SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that the company’s lead product candidate, CAL-101, an oral, delta-selective PI3K inhibitor, has been selected as one of the ‘Top 10 Oncology Projects to Watch’ by Windhover Information.
